RxDoctor Payments Data

David Nieman, PA

Medical · Polson, MTNPI 1760568869

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.

$274in general payments, 2019–2025

Across 16 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$52
  • Merck$45
  • AstraZeneca$39
  • Sanofi-aventis U.S. LLC$30
  • Amgen$19
  • Teva Pharmaceuticals USA, Inc.$18
  • plus $70 from 5 others

What the payments were for

  • Food & beverage$274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$274 in reported general payments places this provider in the 60th percentile of 134 medical providers in Montana.

See all medical providers in Montana

Medicare billing

Part B allowed, 2024
$46,507
Medicare patients
335
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$24,437
EliquisApixaban19$15,763
JardianceEmpagliflozin14$14,296
ValacyclovirValacyclovir Hcl18$1,555
Fentanyl12$785
Atorvastatin Calcium63$706
Gabapentin49$678
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$491
Albuterol Sulfate HfaAlbuterol Sulfate19$395
Levothyroxine Sodium28$310
Levetiracetam12$302
Trazodone Hcl22$296
Tamsulosin Hcl25$277
Meloxicam52$264
Losartan Potassium35$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$16$24,43725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 134 medical providers in Montana.

Other medical in Polson

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →